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Reimagining
your Rx
VCU researchers are redesigning medicines.
In the future, some prescriptions might
be manufactured in a factory the size of a
refrigerator – or even be produced by your body
itself.
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S

ay “prescription medication,” and most
people envision a one-size-fits-all white pill
made in a huge factory far away.
While that picture of pharmaceutical production
may be largely accurate for now, researchers
at VCU are redesigning medicines. What will
your future prescriptions look like? Some of
them might be manufactured in a small portable
factory – or even be produced by your body
itself.
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According to Dr. Thomas Roper, director
of pharmaceutical engineering in VCU’s
Department of Chemical & Life Science
Engineering, tomorrow’s medications are moving
toward manufacturing processes that shrink the
environmental and industrial footprint as they
expand global access to drugs. And those meds
are likely to be more customized to the patient
and easier to take.
“I would say that the theme of my lab is
miniaturization for the purpose of personalized
medicine,” Roper said. “By taking processes
from the macro scale to the micro scale, we are
able to bring science and engineering closer to
the patient.”

Dr. Thomas Roper, director of pharmaceutical engineering in
VCU’s Department of Chemical & Life Science Engineering
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‘By taking processes
from the macro scale to
the micro scale, we are
able to bring science and
engineering closer to the
patient,’ Roper says.

Pharmacy on Demand, a project that Roper
is working on with collaborators from the
Massachusetts Institute of Technology, is an
object lesson in these themes. In this case, the
object is a pharmaceutical factory merely the
size of a refrigerator.
Patients in hard-to-access places often
have to wait for medicine – or go without it
altogether. Pharmacy on Demand is working
on an alternative approach based on small,
configurable pharmaceutical manufacturing
platforms that can ultimately be shipped to
different locations to supply patients with locally
produced, high-quality meds.
Such a strategy would expand access
to pharmaceuticals worldwide, reduce
environmental impact and make the
manufacturing process safer by avoiding the
burden of the construction of manufacturing
sites.
“In my opinion, the biggest advantage of these
miniature manufacturing facilities is footprint,”
Roper said. “Take hydrogen, for example,
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which is highly flammable and explosive. If you
have a big reactor with hydrogen under high
pressure, there are huge safety parameters that
must be accounted for, but a facility this size is
intrinsically safer because there is much less
hydrogen available to react at any one time.”
Roper hopes to initiate work in the area of
biological catalysis that will streamline the
pharmaceutical manufacturing process further.
“Another potential way to manufacture medicines
is biologically,” Roper said. “An area I am
interested in is biological catalysis of reactions,
so eventually you are creating medicines in a
biological host such as E. coli or ultimately even
in a human cell.”
In this paradigm, the medicine is not a tablet
from an amber-colored bottle, but a chemical
process that transfers the manufacturing of the
medicine to the patient’s body.
“In other words, if you string together chemical
transformations that can be done by enzymes in
a cell, you can effectively eliminate the external
manufacturing footprint,” Roper said.
He sees other trends away from the production
of medicines that patients take regularly and
toward the creation of processes that play out
in a patient’s body over time. These include
commercial gene therapies like Strimvelis,
GlaxoSmithKline’s recently approved treatment
for severe combined immunodeficiency or
“bubble boy disease.”
Roper also points to the development of longacting medicines that patients take only once
every 60 to 90 days. When perfected, they may
offer major advantages, including freedom from
the stigma of disease and greater assurance that
patients will actually take their prescriptions.
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Creating ways to
increase patient
compliance with
treatment regimens is
an important aspect of
pharmaceutical research.
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“Patient compliance in pharmaceuticals is
terrible, which reduces the effect of the medical
treatment. Even in cancer treatment, patients
will not always take their medicine when
they are supposed to,” Roper said. Creating
ways to increase patient compliance with
treatment regimens is an important aspect of
pharmaceutical research.
He noted an additional advantage to many of the
next-generation drugs – one harder to quantify.
“There is a general improvement in patient
quality of life,” Roper said. “These treatments
come closer to being cures, so people have to
spend less time feeling like a patient.” •

